dromlakhani Suggest baseline and early follow-up testosterone measurement
STEP 1 — Gather Information
Confirm diagnosis of hypoactive sexual desire disorder (HSDD) in a postmenopausal woman and document intent to initiate testosterone therapy. → Action: Proceed to contraindication assessment.
STEP 2 — Rule In / Rule Out
Assess for absolute contraindications to testosterone therapy (e.g., androgen-sensitive malignancies, uncontrolled cardiovascular disease, pregnancy). → If no contraindications, rule in for baseline T measurement; if contraindications present, rule out and halt therapy initiation.
STEP 3 — Classify or Stratify
Measure baseline total testosterone level using LC-MS/MS or validated assay and classify as subphysiological (<LLN), physiological (within reference range), or supratherapeutic (>ULN) for premenopausal women. → Action: Record baseline value and classification.
STEP 4 — Decide
If baseline is physiological or subphysiological, initiate testosterone therapy at physiological dose and schedule follow-up T measurement at 3–6 weeks; if baseline is supratherapeutic, withhold therapy and investigate for exogenous androgen use or pathology.
Clinical Guardrails / Mimics / Pitfalls
Do not use supra-physiological testosterone doses; avoid oral methyltestosterone due to hepatic toxicity risks; monitor for androgenic adverse effects (acne, hirsutism, voice changes) at each visit; rely on LC-MS/MS for accurate low-level testosterone measurement in women; do not initiate therapy if baseline T is supratherapeutic without investigating etiology.
Concrete Clinical Example
A 55-year-old postmenopausal woman with HSDD begins transdermal testosterone therapy. Baseline T: 12 ng/dL (reference range 8-40 ng/dL). At 5-week follow-up, T: 50 ng/dL (supratherapeutic). Dose reduced by 50%; repeat T at 4 weeks shows 22 ng/dL, within physiological range.
Source: Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, 10.1210/jc.2014-2260